Live Breaking News & Updates on ராஜீவ் மாலிக்

Stay updated with breaking news from ராஜீவ் மாலிக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

How Mylan's Closure Of Its W.Va. Plant Was Years In The Making

There had been warning signs about the Mylan Morgantown plant’s ultimate fate for years, even before the speciality and generic drug manufacturer merged with Pfizer-owned Upjohn to create a new company called Viatris. That merger was finalized in November 2020. ....

Monongalia County , West Virginia , United States , New Jersey , Chestnut Ridge , White Sulphur Springs , Tracey Williams , Mike Puskar , Tracy Lemley , Tom Bloom , Mylan Morgantown , Heather Bresch , Donald Don Panoz , Joseph Gouzd , Robertj Coury , Morgantown Mylan , Rajiv Malik , Douglas Soule Tracey Williams , Joe Manchin , Johanna Puskar , Exchange Commission , Merck Kga , Merck Kgaa , Drug Administration , Us Army , Matrix Laboratories Ltd ,

Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes


Share this article
Share this article
PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/  Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee
® (insulin glargine-yfgn) injection as the first interchangeable biosimilar product under the 351(k) regulatory pathway.
Biocon Biologics
Viatris CEO Michael Goettler commented: We are extremely proud to achieve the industry s first approval of an interchangeable biosimilar product in the U.S., which will help broaden access to this important diabetes medicine for patients, physicians, payers and providers. This is yet another important milestone for our company that not only continues to underscore the strength of our internal scientific capabilities, but also supports our belief in the promising future of our company as we continue to work to identify innovative ways to increase access to co ....

United States , Andhra Pradesh , New Zealand , Kiran Mazumdar Shaw , Rajiv Malik , Arun Chandavarkar , Biocon Biologics , Viatris Biocon Biologics , European Free Trade Association , Exchange Commission , Pfizer Inc , European Union , Viatris Inc , Viatris President Rajiv Malik , Executive Chairperson , Biosimilar Insulin Glargine , Biologics Managing Director Arun Chandavarkar , Biocon Biologic , Global Healthcare , Biologics Limited , Biocon Limited , Generic Formulations , Looking Statements , Private Securities Litigation Reform Act , Fair Disclosure , Neither Biocon ,